Overview

Safety and Efficacy of CC-10004 for Prurigo Nodularis

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This trial will include: - Study period up to 7 months. - Office visits monthly lasting approximately 1 hour. - Blood Draws. - Oral medication that is taken 2 times daily. - Photographs and biopsies if agreed.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborator:
Celgene Corporation
Treatments:
Apremilast
Thalidomide